ClinicalTrials.gg
CompletedNCT06067568Updated Mar 15, 2024

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

A Phase 1 interventional study of Lutikizumab Dose A and Lutikizumab Dose B in Healthy Volunteers, sponsored by AbbVie. Completed at 3 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to compare the bioavailability of two different formulations of lutikizumab, and to assess adverse events (AEs) and how lutikizumab moves through the body in healthy Chinese participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Lutikizumab
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female healthy volunteers aged between 18 and 60 years.

    -- Part 2 only: Participant must be first-generation Han Chinese of full Chinese parentage residing outside of China. Participant must maintain a typical Chinese lifestyle, including consuming a typical Chinese diet.

  • \<= 18.0 to \<= 29.9 kg/m\^2 after rounding to the tenths decimal, at screening and upon initial confinement.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and 12-lead (ECG).

Exclusion criteria

Exclusion Criteria:

  • Use any medications, vitamins, and/or herbal supplements within the 2 week period or 5 half-lives (whichever is longer) prior to study drug administration.
  • History of: epilepsy, any cardiac, respiratory (except mild asthma), renal, hepatic ,gastrointestinal, hematologic, demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease, glaucoma, psychiatric disease or disorder, or any uncontrolled medical illness.
  • Prior exposure to lutikizumab.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Part 1, Dose A

    Participants will receive a single dose of Lutikizumab Dose A.

    Drug: Lutikizumab Dose A

  • Experimental
    Part 1, Dose B

    Participants will receive a single dose of Lutikizumab Dose B.

    Drug: Lutikizumab Dose B

  • Experimental
    Part 2

    Han Chinese participants will receive a single dose of Lutikizumab.

    Drug: Lutikizumab Dose A

Interventions

  • DrugLutikizumab Dose A

    Injection; subcutaneous (SC)

  • DrugLutikizumab Dose B

    Injection; subcutaneous (SC)

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of Lutikizumab

    Cmax of lutikizumab will be assessed.

    Time frame: Up to Day 8

  2. Time to Cmax (Tmax) of Lutikizumab

    Tmax of lutikizumab will be assessed.

    Time frame: Up to Day 8

  3. Apparent Terminal Phase Elimination Rate Constant (β) of Lutikizumab

    Apparent terminal phase elimination rate constant (β) of lutikizumab will be assessed.

    Time frame: Up to Day 8

  4. Terminal Phase Elimination Half-life (t1/2) of Lutikizumab

    Terminal phase elimination half-life (t1/2) of lutikizumab will be assessed.

    Time frame: Up to Day 8

  5. Area under the Serum Concentration-time Curve (AUC) from Time 0 to the Time of the Last Measurable Concentration (AUC0-t) of Lutikizumab

    AUC0-t of lutikizumab will be assessed.

    Time frame: Up to Day 8

  6. AUC from Time 0 to Infinity (AUC0-inf) of Lutikizumab

    AUC0-inf of lutikizumab will be assessed.

    Time frame: Up to Day 8

  7. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Baseline to Day 71

07

Study locations

3 sites
  • Altasciences Clinical Los Angeles, Inc /ID# 260986
    Cypress, California 90630, United States
  • Acpru /Id# 259029
    Grayslake, Illinois 60030, United States
  • PPD Clinical Research Unit - Austin /ID# 260141
    Austin, Texas 78744, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Feb 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2023
First posted
Oct 5, 2023
StartActual
Sep 28, 2023
Primary completionActual
Feb 26, 2024
CompletionActual
Feb 26, 2024
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06067568
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 5, 2023
Start date
Sep 28, 2023
Primary completion
Feb 26, 2024
Completion
Feb 26, 2024
Last update
Mar 15, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion